Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.50 |
| ▸ | USP7 | Q93009 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709795 | 0.92 | MAPT (0.59) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL19400776 | 0.80 | MAPT (0.56) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL1744852 | 0.80 | MAP4K4 (0.49) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL712180 | 0.79 | PIK3CD (0.43) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL15785404 | 0.77 | MAP4K4 (0.71) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL14909752 | 0.77 | MAPT (0.61) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL29361094 | 0.77 | MAP4K4 (0.71) | MAPTCASP1GSK3BMAP4K4USP7 | |
| SCHEMBL2967597 | 0.77 | LRRK2 (0.55) | MAPTCASP1MAP4K4USP7FYN | |
| SCHEMBL971373 | 0.75 | MAP4K4 (0.80) | MAP4K4USP7FYNMKNK1CHEK2 | |
| SCHEMBL1519413 | 0.75 | AURKA (0.61) | MAPTCASP1MAP4K4USP7PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | MAPT 3074/4885CASP1 700/4885GSK3B 3429/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | MAPT 4149/4885CASP1 206/4885GSK3B 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.